biotechnology

Clinical-stage biotech Spyre Therapeutics announced $300M public offering with $45M underwriter option, led by Jefferies and Goldman Sachs, targeting IBD treatments.

Neomorph closes $100M Series B led by Deerfield Management to advance NEO-811, its molecular glue degrader for kidney cancer, and expand its pipeline.

Global centrifugal separator market projected to reach $10.14B by 2035 from $4.62B in 2025, growing at 7.3% CAGR driven by pharma, biotech, and food processing demand.

Adaptive Biotech insider sold $554K in shares via routine plan; company posted 55% revenue growth and dramatically narrowed losses, signaling operational inflection.

Artiva Biotherapeutics to present AlloNK cell therapy pipeline at Needham Healthcare Conference on April 15, 2026, advancing three ongoing autoimmune disease trials.

$AVAI and Austrianova present latest α-Klotho therapy data at Second Annual Klotho Conference in September, highlighting Cell-in-a-Box® technology for longevity protein production.

Serina's Chief Development Officer to present novel POZ-based lipid nanoparticles that eliminate PEG immunogenicity issues, showing no antibody response in preclinical studies.

Celldex Therapeutics closed $345M public offering at $29/share with full underwriter option exercise, netting approximately $401M in total gross proceeds.

Xilio Therapeutics granted stock options for 3,257 shares to two new employees at $8.48 exercise price, reflecting typical equity compensation practices for biotech hiring.

FibroBiologics prices $3M offering and validates manufacturing of CYWC628 for diabetic ulcer trials while restoring Nasdaq compliance.

Adaptive Biotechnologies' president sold $1.21M in shares via pre-planned transaction, yet retains substantial holdings. Stock up 51% annually as core MRD business surges.

Alvotech files 2025 annual report with SEC, reporting five marketed biosimilars and nine additional candidates in development across therapeutic areas.

Alvotech files 2025 annual report showing five approved biosimilars and nine pipeline candidates across multiple therapeutic areas, positioning the company amid rapid biosimilar market growth.

Alvotech files 2025 annual SEC report with five marketed biosimilars and nine pipeline candidates supported by global partnerships.

Orbis Investment Management discloses 4.99% stake in Genmab A/S, holding 3.2M shares, signaling institutional confidence in the Danish biotech firm's strategy.

Damora Therapeutics appoints Jennifer Jarrett as CEO, grants her 2M share awards. Company also awards equity to four new employees under Nasdaq inducement rules.

Liquidia's Chief Commercial Officer sold 80,000 shares worth $2.8M through pre-arranged plan while retaining substantial holdings as flagship product Yutrepia drives record quarterly profits.

Novartis to acquire allergy biotech Excellergy for up to $2 billion, gaining first-in-class ECRI technology and lead candidate Exl-111 currently in Phase 1 trials.

Adaptive Biotechnologies COO Julie Rubinstein sold 179,703 shares for $2.37M via pre-arranged tax plan as company posts strong 55% revenue growth.

Polyrizon files 2025 annual report detailing its pre-clinical intranasal hydrogel technology platform targeting viral and allergen protection.